Mark William Conley - 04 Jun 2024 Form 3 Insider Report for SAB Biotherapeutics, Inc. (SABS)

Role: Interim Chief Financial Officer, Vice President of Finance
Signature: Mark Conley
Issuer symbol: SABS
Transactions as of: 04 Jun 2024
Net transactions value: $0
Form type: 3
Filing time: 24 Jun 2024, 17:00:12 UTC
Previous filing: 17 Mar 2022
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	SABS	Employee Stock Option (right to buy)							04 Jun 2024	Common Stock	25,000	$4.79	Direct	F1, F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares underlying the option vest over a four-year period, vesting 1/4 on the one-year anniversary of the date of grant, and the remaining 3/4 vesting pro rata on a monthly basis in 36 equal installments thereafter. The options were granted on November 6, 2023.
F2	Represents options to purchase shares of common stock pursuant to the Registrant's 2021 Omnibus Equity Incentive Plan.
F3	Reflects the 1-for-10 reverse stock split of the Registrant's common stock, which became effective January 5, 2024.

Remarks:

Interim Chief Financial Officer, Vice President of Finance